|The University of Adelaide||Home | Faculties & Divisions | Search|
|Faculties & Divisions | People A to Z | Media Expertise | Phonebook||
|Public browsing [Login]|
Dr Andrew Somogyi
To link to this page, please use the following URL:
Andrew is Professor in Clinical and Experimental Pharmacology.
He is a practicing pharmacist, having graduated from the Tasmanian College of Advanced Education in 1972. He undertook a higher degree (Master of Science-1978) and then PhD (1982) at Sydney University, School of Pharmacy. Andrew then undertook postdoctoral research at the Medical Hospital of the University of Bonn in Germany for 2.5 years under the mentorship of Prof Roland Gugler and Prof Michel Eichelbaum. Following a short period in Melbourne at the then Baker Medical Research Institute in Melbourne, he was recruited as a Research Fellow to the Department of Clinical & Experimental Pharmacology at the University of Adelaide in late 1982. In 1992 he was appointed as Senior Lecturer, then promoted to Associate Professor (1994) and Professor in 2002. He was Deputy Head of the Department between 1992 and 2010. Between May 2005 and December 2010, he was Associate Dean (Research) of the Faculty of Health Sciences. In 2010 he was made an Honorary Fellow of the Faculty of Pain Medicine the Australian and New Zealand College of Anaesthetists.
Andrew teaches pharmacology in undergraduate medicine, dentistry, nursing and health science programs. He has an active research program centred on elucidating the dispositional mechanisms for altered human drug response in pain therapeutics, cancer and transplantation through pharmacokinetic, metabolism, pharmacodynamic and pharmacogenomic studies. He has translated his research into clinical practice by establishing a Pharmacogenetics Service at the Royal Adelaide Hospital. Pharmacogenomics and personalised healthcare is a theme of his overarching research and public health focus.
He provides regular consultancy on the role of pharmacogenomics in adverse drug reactions to clinicians, patients and the legal profession Australia-wide.
PhC (Certificate of Pharmacy), Tasmanian College of Advanced Education
Diploma of Hospital Pharmacy, Sydney University
Master of Science, Sydney University
PhD (Clinical Pharmacology), Sydney University
Awards & Achievements
2007: Best Oral Presentation in Clinical Toxicology- 10th International Congress of IATDMCT (Nice, France)
2010: Honorary Fellow of the Faculty of Pain Medicine (Australian and New Zealand College of Anaesthetists)
He teaches undergraduate Medical, Dental, Science, Health Science and Nursing students and has the capability of teaching any area of pharmacology- clinical pharmacology.
He is currently assessing the use of iPad and its applications for undergraduate student learning.
He has an international research track record in pharmacokinetics, drug metabolism, pharmacogenetics and genomics and pharmacokinetic/pharmacodynamic relationships with specific reference to the opioid class of drugs.
Pain- pharmacogenomics of acute and chronic analgesic therapy; symptom control therapy
Palliative Medicine- ketamine, symptom control therapy
Addictions - immune pathway genetics
Organ Transplantation - Transporters, metabolism and pharmacogenetics of immunosuppressants
Leukaemias - tyrosine kinase inhibitors: population pharmacokinetics, genetics and response
He has a growing international standing in pharmacogenetics and pharmacogenomics-personalised healthcare.
He is the regional member of the International Union of Basic and Clinical Pharmacology (IUPHAR) Subcommittee on Pharmacogenomics.
Editorial Board Membership
British Journal of Clinical Pharmacology (Senior Editor)
Pharmacogenetics and Genomics
Pharmacogenomics and Personalized Medicine
European Journal of Clinical Pharmacology
Journal of Opioid Management
Research Training: He has an active Research Training Scheme programme and is currently supervising 6 PhD students. Over the last 4 years he has had 14 students who were finalists at nationally competitive scientific meeting with 4 students being awarded first prize (2005, 2006, 2009, 2010).
Potential PhD Projects available:
Fentanyl pharmacogenetics in acute and chronic pain
Nilotinib pharmacokinetics-pharmacodynamics-pharmacogenomics in leukaemia
Genetics of transition from acute to chronic pain
GWAS studies in severe adverse drug reactions.
His research program has been funded by the NHMRC continuously since 1999 and has had NIH, Leukaemia & Lymphoma Society (USA), National Heart Foundation, Alcohol Education and Research, Kidney Australia and ANZCA support over the last 5 years .
Leukemia and Lymphoma Society Translational Research Grant (USA). The role of OCT-1 Activity enhancers in improving the response of patients with low OCT-1 activity to imatinib. White D, Hughes T, Somogyi A, Melo J. 2009-2011 [US$600,000]
NHMRC 2011-2012: TIR Signalling pathway pharmacogenomics and opioid response: beyond the mu opioid receptor. Somogyi A. Project Grant: $240,000 2 years.
NHMRC 2009-2011: Pharmacogenetics of methadone maintenance treatment. Somogyi A & Coller J. Project Grant. $342,000.
NHMRC 2009-2011: Pharmacogenomics of renal transplantation. Sallustio BC, Coller JK, Morris RG, Somogyi AA. $344,000.
NHMRC 2009-2011: The cognitive impact of opioids during chronic administration. White JM, Nettlebeck TJ, Burns NR, Somogyi AA. $380,000
Google Scholar link to my publications
Consistently publishes in the top ranking clinical pharmacology (Clinical Pharmacology & Therapeutics, British Journal of Clinical Pharmacology), pain (Pain) and addiction (Addiction Biology) journals.
H-index of 44
Publications since 2010:
Somogyi AA. Pharmacogenetics in Palliative Care (chapter 8), in Pharmacogenetics: making Cancer treatment safer and more effective. Newman WG (ed). Springer (Heidelberg) p 115-125, 2010
Somogyi AA and Hardy J. Role of pharmacogenomics in pain therapy: focus on opioids. Cancer Forum 34, 74-77, 2010
Upton RN, Somogyi AA, Martinez AM, Colvill J, Grant C. Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. British Journal of Anaesthesia 105, 798-809, 2010
Gordon AL, Lopatko OV, Somogyi AA, Foster DJ, White AM. (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. British Journal of Clinical Pharmacology 70, 895-902, 2010.
Grace PM, Hutchinson MR, Manavis J, Somogyi AA, Rolan PE. A novel animal model of graded neuropathic pain: utility to investigate mechanisms of population heterogeneity. Journal of Neuroscience Methods 193, 47-53, 2010.
Raungrut P, Uchaipichat V, Elliot DJ, Janchawee B, Somogyi AA, Miners JO. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. Journal of Pharmacology and Experimental Therapeutics 334, 609-618, 2010.
Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, Somogyi AA, Yin H, Maier SF, Rice KC, Watkins LR. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 167, 880-893, 2010
Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kullenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12, 113-124, 2011.
Hay JL, La Vincente SF, Somogyi AA, Chapleo CB, White JM. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. European Journal of Pain 15, 293-298, 2011.
Huxtable CA, Roberts LJ, Somogyi AA, Macintyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesthesia and Intensive Care 39, 804-823, 2011.
Wu Y, Lousberg EL, Moldenhauer LM, Hayball JD, Robertson SA, Coller JK, Watkins LR, Somogyi AA, Hutchinson MR. attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. Brain, Behavior, and Immunity 25, S155-S164, 2011.
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists : President 2006 - 2007; Honorary Secretary 1998-02
Professional Association Membership:
Australasian Society of Clinical and Experimenatl Pharmacologists & Toxicologists (ASCEPT)
Australian Pain Society (APS)
Australian Pharmaceutical Sciences Association (APSA)
American Society of Clinical Pharmacology and Therapeutics (ASCPT)
British Pharmacolgocal Society (BPS)
International; Society for the Study of Xenobiotics (ISSX)
International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
Australian and New Zealand College of Anaesthetists (ANZCA): Faculty of Pain Medicine (FPM)
Advisory Committee on NonPrescription Medicines (TGA)- Member
Australian Medicines Handbook (AMH) Pty.Ltd: Board Member
Expertise for Media Contact
Copyright © 2013 The University of Adelaide
Last Modified 26/07/2013 Marketing & Communications
CRICOS Provider Number 00123M